Because the inhibition of mTORC1 produce pleiotropic results and induce side effects that can mask its therapeutic potential, we also tested the treatment with two molecules that can modulate specific mTORC1 downstream pathways, i.e.: trehalose, that can induce autophagy in an mTOR-independent manner and it has been considered as a neuroprotector in some neurodegenerative diseases [5]; and PF-4708671, that inhibits the protein and lipid synthesis by the specific inhibition of the S6K1 protein [6]. The gene discussed is MTOR; the disease is neurodegenerative disease.